Genocea Biosciences (GNCA) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock GNCA vs. SMFL, NEXI, SCPS, VAXX, STAB, NAVB, TRVN, EVLO, GNCAQ, and CMRAShould you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Smart for Life (SMFL), NexImmune (NEXI), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Statera Biopharma (STAB), Navidea Biopharmaceuticals (NAVB), Trevena (TRVN), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), and Comera Life Sciences (CMRA). These companies are all part of the "pharmaceutical products" industry. Genocea Biosciences vs. Its Competitors Smart for Life NexImmune Scopus BioPharma Vaxxinity Statera Biopharma Navidea Biopharmaceuticals Trevena Evelo Biosciences Genocea Biosciences Comera Life Sciences Genocea Biosciences (NASDAQ:GNCA) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations. Is GNCA or SMFL more profitable? Smart for Life's return on equity of 0.00% beat Genocea Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Genocea BiosciencesN/A -182.88% -62.76% Smart for Life N/A N/A N/A Does the media refer more to GNCA or SMFL? In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score. Company Overall Sentiment Genocea Biosciences Neutral Smart for Life Neutral Do insiders and institutionals believe in GNCA or SMFL? 0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 31.7% of Smart for Life shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, GNCA or SMFL? Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Smart for Life has a beta of 17.06, suggesting that its stock price is 1,606% more volatile than the S&P 500. Which has better valuation and earnings, GNCA or SMFL? Smart for Life has higher revenue and earnings than Genocea Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenocea Biosciences$1.91M0.00-$33.20M-$0.61N/ASmart for Life$11.11M0.00-$22.68MN/AN/A SummarySmart for Life beats Genocea Biosciences on 7 of the 7 factors compared between the two stocks. Get Genocea Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart GNCA vs. The Competition Export to ExcelMetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6K$297.91M$5.70B$10.42BDividend YieldN/AN/A5.78%4.69%P/E Ratio0.00N/A75.6626.31Price / SalesN/A452.13540.19125.23Price / CashN/A22.4425.6730.68Price / BookN/A10.2812.856.40Net Income-$33.20M-$111.61M$3.29B$276.69M Genocea Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070SMFLSmart for LifeN/A$0.00+100.0%N/A-93.2%$21K$11.11M0.00110Gap UpNEXINexImmuneN/A$0.01flatN/A-99.9%$14KN/A0.0070SCPSScopus BioPharmaN/A$0.00flatN/A+0.0%$13KN/A0.009High Trading VolumeVAXXVaxxinityN/A$0.00flatN/A-50.0%$13KN/A0.0090Gap UpSTABStatera BiopharmaN/A$0.00+100.0%N/AN/A$11KN/A0.0020Gap UpNAVBNavidea BiopharmaceuticalsN/A$0.00-80.0%N/A-80.0%$10K$8.13K0.0010Gap DownTRVNTrevena1.8391 of 5 stars$0.01-96.0%$5.00+49,900.0%-99.7%$10K$443K0.0040Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070CMRAComera Life SciencesN/A$0.00-50.0%N/AN/A$3K$1.00M0.002Gap Down Related Companies and Tools Related Companies SMFL Competitors NEXI Competitors SCPS Competitors VAXX Competitors STAB Competitors NAVB Competitors TRVN Competitors EVLO Competitors GNCAQ Competitors CMRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNCA) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNCA Stock Alerts